Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program

Study Overview
=================
Brief Summary
-----------------
The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was generated to describe their baseline demographic and clinical characteristics.

Detailed Description
-----------------
The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. PSS data was obtained from patients with wet AMD who enrolled in the program for the index period 10/10/2019 to 04/30/2020. Identification period of the index period: 10/10/2019 to 04/30/2020 Index date: Date of enrollment in the PSS program Study Period: 10/10/2019 to 04/30/2020

Official Title
-----------------
Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program

Conditions
-----------------
Age-related Macular Degeneration (AMD)

Intervention / Treatment
-----------------
* Other: All participants


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients were enrolled in the brolucizumab PSS program ≥19 years old Exclusion Criteria: • None

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All Participants<br>All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program | Other: All participants<br>* All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with Primary plan type | The primary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The primary Plan type include commercial, government or other insurance. | Index date defined as the date of enrollment in the PSS program | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Age | Age information of patients enrolled in the brolucizumab PSS program was reported | Index date defined as the date of enrollment in the PSS program | 
| Gender | Gender information of patients enrolled in the brolucizumab PSS program was reported | Index date defined as the date of enrollment in the PSS program | 
| Patient region (by state) | Distribution of patients across US states | Index date defined as the date of enrollment in the PSS program | 
| Provider region (by state) | Number of providers and their distribution across US states | Index date defined as the date of enrollment in the PSS program | 
| Insurance coverage | The insurance coverage details for all the patients with wet AMD was reported | Index date defined as the date of enrollment in the PSS program | 
| Number of patients with Secondary plan type | The secondary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The secondary plan included commercial, government or other insurance | Index date defined as the date of enrollment in the PSS program | 
| Disease Status | The eye disease status of all the patients were reported. Disease status was categorized as Right eye, left eye, or bilateral | Index date defined as the date of enrollment in the PSS program | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Primary plan,, AMD characteristics,, brolucizumab